Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Odintsov

Showing results (191-200 of 196) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 196 results.
The American Journal of Surgical Pathology|August 1, 2025
High-Grade Early-Onset Prostate Cancer: Assessment of TMPRSS2::ERG-Negative Tumors Suggests Low Frequency of Germline Alterations and a Pathogenic Role for HOXB13Daisy Maharjan, Stephanie Siegmund, Květoslava Michalova, et al.
Nature Cancer|October 9, 2023
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutationsIsao Miyazaki, Igor Odintsov, Keiji Ishida, et al.
Nature Cancer|September 24, 2023
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutationsIsao Miyazaki, Igor Odintsov, Keiji Ishida, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2026
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted TherapiesM Aldea, S Lenahan, M-A Locquet, et al.
Cancer Discovery|April 9, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET RearrangementsSeshiru Nakazawa, Federica Pecci, Igor Odintsov, et al.
Cancer Cell|March 6, 2026
Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancerMarco Campisi, Tatsuya Osaki, Ian Dryg, et al.
Pageof 20

Showing results (191-200 of 196) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 196 results.
The American Journal of Surgical Pathology|August 1, 2025
High-Grade Early-Onset Prostate Cancer: Assessment of TMPRSS2::ERG-Negative Tumors Suggests Low Frequency of Germline Alterations and a Pathogenic Role for HOXB13Daisy Maharjan, Stephanie Siegmund, Květoslava Michalova, et al.
Nature Cancer|October 9, 2023
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutationsIsao Miyazaki, Igor Odintsov, Keiji Ishida, et al.
Nature Cancer|September 24, 2023
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutationsIsao Miyazaki, Igor Odintsov, Keiji Ishida, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2026
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted TherapiesM Aldea, S Lenahan, M-A Locquet, et al.
Cancer Discovery|April 9, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET RearrangementsSeshiru Nakazawa, Federica Pecci, Igor Odintsov, et al.
Cancer Cell|March 6, 2026
Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancerMarco Campisi, Tatsuya Osaki, Ian Dryg, et al.
Pageof 20